Search results
Results from the WOW.Com Content Network
An alternative to "race-based medicine" is personalized or precision medicine. [65] Precision medicine is a medical model that proposes the customization of healthcare, with medical decisions, treatments, practices, or products being tailored to the individual patient. It involves identifying genetic, genomic (i.e., genomic sequencing), and ...
In August 2020, the U.S. Food and Drug Administration (FDA) became aware of nitrosamine impurities in certain samples of rifampin. [61] The FDA and manufacturers are investigating the origin of these impurities in rifampin, and the agency is developing testing methods for regulators and industry to detect the 1-methyl-4-nitrosopiperazine (MNP ...
Clayton and Byrd write that there have been two periods of health reform specifically addressing the correction of race-based health disparities. The first period (1865–1872) was linked to Freedmen's Bureau legislation and the second (1965–1975) was a part of the Civil Rights Movement. Both had dramatic and positive effects on black health ...
Race adjustment, also known as race-correction, [1] [2] is the calculating of a result which takes into account race. [1] It is commonly used in medical algorithms in several specialties, including cardiology , nephrology , urology , obstetrics , endocrinology , oncology and respiratory medicine . [ 1 ]
Rifampin rapidly kills fast-dividing bacilli strains as well as "persisters" cells, which remain biologically inactive for long periods of time that allow them to evade antibiotic activity. [7] In addition, rifabutin and rifapentine have both been used against tuberculosis acquired in HIV-positive patients.
Management of tuberculosis refers to techniques and procedures utilized for treating tuberculosis (TB), or simply a treatment plan for TB.. The medical standard for active TB is a short course treatment involving a combination of isoniazid, rifampicin (also known as Rifampin), pyrazinamide, and ethambutol for the first two months.
Recent interest in race-based medicine, or race-targeted pharmacogenomics, has been fueled by the proliferation of human genetic data which followed the decoding of the human genome in the first decade of the twenty-first century. There is an active debate among biomedical researchers about the meaning and importance of race in their research.
It revealed that only 4.5% of the case studies mentioned a racial or ethnic background of the patient and when the patient was black or had "potentially unfavorable characteristics" race or ethnicity was more likely to be identified. There was also a greater prevalence of health-related themes discussed when race or ethnicity was identified.